LivaNova (LIVN) Net Margin (2014 - 2026)

LivaNova (LIVN) posted Net Margin of 6.39% for Q1 2026, down 25.41% sequentially from 8.57% in Q4 2025, and up 10969.0% YoY from N/an in Q1 2025.

LivaNova (LIVN) Net Margin (2014 - 2026) Analysis & Trends

LivaNova has reported Net Margin for 12 years, with the latest figure at 6.39% in Q1 2026.

Quarterly Net Margin rose 10969.0% year-over-year to 6.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.54% (up 2495.0% YoY) and the FY2025 annual result came in at 17.46%, down 2251.0% from the prior year.
Net Margin declined to 6.39% in Q1 2026 per LIVN's latest filing, from 8.57% in the prior quarter.
Over five years, Net Margin peaked at 17.37% in Q4 2024 and troughed at 103.3% in Q1 2025.
A 5-year average of 4.87% and a median of 5.14% in 2024 frame the typical range for Net Margin.
The sharpest annual moves came in 2025 and 2026: Net Margin plunged 8908 bps in 2025, then surged 10969 bps in 2026.
Over 5 years, Net Margin stood at 0.61% in 2022, then surged by 758 bps to 5.27% in 2023, then soared by 229 bps to 17.37% in 2024, then slumped by 51 bps to 8.57% in 2025, then retreated by 25 bps to 6.39% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 6.39%, 8.57%, and 7.49% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Abbott Laboratories	199.63 Bn	194.02 Bn	7.27 Bn	7.37%
2	Stryker	127.42 Bn	123.95 Bn	4.50 Bn	19.37%
3	Medtronic	118.97 Bn	109.75 Bn	6.41 Bn	12.84%
4	Boston Scientific	73.39 Bn	72.85 Bn	3.85 Bn	16.67%
5	Edwards Lifesciences	51.97 Bn	47.72 Bn	1.35 Bn	13.87%
6	Dexcom	34.32 Bn	32.37 Bn	830.00 Mn	19.04%
7	GE HealthCare Technologies	33.76 Bn	31.65 Bn	2.18 Bn	10.84%
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn	6.47%
9	Steris	23.04 Bn	22.56 Bn	684.20 Mn	13.47%
10	LivaNova	4.31 Bn	3.79 Bn	273.67 Mn	27.83%

Download Data